Almitrine Bismesylate + Raubasine: Brands, Price & Uses in Bangladesh

Almitrine Bismesylate + Raubasine is a combination product that has historically been marketed (mainly in parts of Europe, Asia, and other regions, including Bangladesh) for a limited set of circulatory and neurosensory complaints, mostly in older adults. Evidence for meaningful clinical benefit from modern controlled trials is limited, and the product has been withdrawn in some countries on safety grounds; it should be regarded as an adjunctive or symptomatic therapy rather than a disease-modifying treatment.

Guideline/label-supported uses

• Adjunct in recovery after ischaemic cerebral stroke: used as a supportive measure alongside standard stroke rehabilitation to help reduce neurological deficit and support functional recovery.
• Age-related neurosensory and cognitive-behavioural complaints: symptoms such as reduced concentration, memory difficulty, dizziness, and mood/behavioural changes associated with cerebral circulatory insufficiency in elderly patients.
• Chorioretinal circulatory disorders: visual disturbances attributed to impaired choroidal/retinal blood flow.
• Cochleo-vestibular disorders: hearing loss, tinnitus, and vertigo attributed to impaired inner-ear microcirculation.

Evidence caveat

Modern systematic reviews have found the quality and quantity of trial evidence for Almitrine Bismesylate + Raubasine in these indications to be limited, and regulatory agencies in some countries have restricted or withdrawn oral almitrine-containing products due to safety concerns (see Precautions and Warnings). Almitrine Bismesylate + Raubasine should only be used under a physician's guidance, with the treatment goal and duration reassessed periodically.

Adult dose

Treatment should be initiated and supervised by a physician, and the response reassessed periodically (typically every few months) to confirm continued benefit, since evidence for long-term benefit of Almitrine Bismesylate + Raubasine is limited.

Pediatric dose

Not established; Almitrine Bismesylate + Raubasine is not indicated for use in children (see Pediatric Uses).

Renal/hepatic adjustment

Almitrine Bismesylate + Raubasine is contraindicated in severe hepatic impairment (see Contraindications). No well-established dose adjustment for renal impairment has been defined; use with caution and close monitoring in patients with significant renal impairment.

Reported adverse effects of Almitrine Bismesylate + Raubasine include:

• Common: unintended weight loss, nausea, epigastric/stomach discomfort, and other gastrointestinal complaints; insomnia, drowsiness, anxiety, dizziness, and palpitations.
• Neurological (important): peripheral neuropathy — numbness, tingling, or weakness in the hands and feet — has been specifically and repeatedly associated with almitrine, particularly with prolonged use or in patients with pre-existing neuropathy risk factors (e.g., diabetes, chronic alcohol use). This can be serious and, in some reported cases, only partially reversible. Patients should be advised to report any numbness, tingling, or weakness promptly, and Almitrine Bismesylate + Raubasine should be discontinued if these occur (see Precautions and Warnings).